Solid Tumours and Chromosome Aberrations as Late Side Effects of Melphalan Therapy in Ovarian Carcinoma

Authors

  • N. Einhorn Department of Gynecological Oncology, Radiumhemmet; The Cancer Epidemiological Unit, Karolinska Institute; The Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden
  • G. Eklund Department of Gynecological Oncology, Radiumhemmet; The Cancer Epidemiological Unit, Karolinska Institute; The Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden
  • B. Lambert Department of Gynecological Oncology, Radiumhemmet; The Cancer Epidemiological Unit, Karolinska Institute; The Department of Clinical Genetics, Karolinska Hospital, Stockholm, Sweden

DOI:

https://doi.org/10.3109/02841868809093528

Keywords:

Chemotherapy; ovarian cancer, melphalan, chro- mosome aberrations, secondary solid tumours

Abstract

Fifty-five ovarian cancer patients treated with melphalan during 1968–1978 were followed during 309 person years and studied with cytogenetic analyses. During the clinical follow-up 7 patients developed a new primary solid tumour. The excess risk of developing new primary solid tumours in patients treated with melphalan was statistically significant (p < 0.05) and the relative risk corresponded to 3.0. Patients developing a new solid tumour showed a similar pattern of chromosome aberrations in the peripheral lymphocytes to that previously shown for the whole cohort.

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Einhorn, N., Eklund, G., & Lambert, B. (1988). Solid Tumours and Chromosome Aberrations as Late Side Effects of Melphalan Therapy in Ovarian Carcinoma. Acta Oncologica, 27(3), 215–219. https://doi.org/10.3109/02841868809093528

Issue

Vol. 27 No. 3 (1988): Acta Oncologica

Section

Articles